SABS
NASDAQ
$3.48
SAB Biotherapeutics Inc (SABS)
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $10.10 (+190.23%)
Market Cap
$273M
P/E Ratio
14.06
Free Cash Flow Yield
-19.50%
Beta (5Y)
0.78
Price Chart
Valuation
Market Cap$273M
P/E14.06
P/S2.96
P/B1.21
Profitability
Gross Profit (TTM)-$33M
EBITDA-$55M
EPS$0.26
Financial Health
Free Cash Flow Yield-19.50%
Growth & Risk
Beta (5Y)0.78
Sharpe Ratio1.06